{
    "2021-12-31": [
        [
            {
                "time": "",
                "original_text": "复星医药：董事会会议审议通过关于受让重庆复创医药研究有限公司23.9992%股权的议案",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重庆复创",
                        "股权受让",
                        "董事会"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药产业拟出资1.41亿美元增持重庆复创24%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重庆复创",
                        "增资",
                        "股权增持"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196.SH)：子公司拟以1.41亿美元受让重庆复创23.9992%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重庆复创",
                        "股权受让",
                        "子公司"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药(600196.SH)子公司拟1.41亿美元受让小分子靶向药物企业重庆复创24%股权",
                "features": {
                    "keywords": [
                        "复星医药",
                        "重庆复创",
                        "小分子靶向药物",
                        "股权受让"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "复星医药5500万打水漂 终止引进的SGLT-2抑制剂开发",
                "features": {
                    "keywords": [
                        "复星医药",
                        "SGLT-2抑制剂",
                        "项目终止",
                        "研发投入"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}